IBB: iShares Nasdaq Biotechnology ETF - MutualFunds.com
Continue to site >
Trending ETFs

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Rating
Sector Rating
Recommendation *
Avoid
Neutral
Fair
Quality
Rating Breakdown
Avg.
Relative Strength
The relative strength of a dividend stock indicates whether the stock is uptrending or not. The major determining factor in this rating is whether the stock is trading close to its 52-week-high.
Overall Yield Attractiveness
If a stock’s yield is above or near the market average then it will be rated higher within this parameter. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors.
Dividend Reliability
A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. A company that pays out close to half its earnings as dividends and retains the other half of earnings has ample room to grow its business and pay out more dividends in the future.
Dividend Uptrend
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
Earnings Growth
A stock’s Earnings Growth rating evaluates a company’s expected EPS for the current financial year and compares it to next financial year’s expected EPS. Stocks with single-digit growth estimates will have a higher rating than others, as our research has shown that well-established dividend-paying companies have modest earnings growth estimates.
Upgrade to Premium to get unlimited access to Ratings, Recommendations, Payout Estimates, and more.

iShares Nasdaq Biotechnology ETF

IBB - Snapshot

Vitals

  • YTD Return 6.7%
  • 3 Yr Annualized Return 12.6%
  • 5 Yr Annualized Return 6.3%
  • Net Assets $10.4 B
  • Holdings in Top 10 42.5%

52 WEEK LOW AND HIGH

$161.87
$94.39
$161.87

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.46%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 29.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

Compare IBB to Popular Health Care Sector Equity Funds and ETFs

Overview

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Vanguard Health Care Fund

Fund

$223.19

+0.14%

$49.03 B

0.85%

$1.89

3.47%

-

Health Care Select Sector SPDR® Fund

XLV | ETF

$116.97

+0.31%

$25.69 B

1.45%

$1.69

3.11%

-

T. Rowe Price Health Sciences Fund

Fund

$104.19

-0.16%

$17.43 B

-

$0.00

5.40%

-

Vanguard Health Care Index Fund

Fund

$116.28

+0.15%

$15.36 B

1.17%

$1.36

3.90%

-

Vanguard Health Care Index Fund

VHT | ETF

$232.30

+0.02%

$15.36 B

1.17%

$2.71

3.83%

-

IBB - Profile

Distributions

  • YTD Total Return 6.7%
  • 3 Yr Annualized Total Return 12.6%
  • 5 Yr Annualized Total Return 6.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.24%
DIVIDENDS
  • Dividend Yield 0.2%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    iShares Nasdaq Biotechnology ETF
  • Fund Family Name
    iShares
  • Inception Date
    Feb 05, 2001
  • Shares Outstanding
    68500000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Greg Savage

Fund Description

The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

IBB - Performance

Return Ranking - Trailing

Period IBB Return Category Return Low Category Return High Rank in Category (%)
YTD 6.7% 1.3% 15.8% 13.95%
1 Yr 25.9% 3.0% 180.5% 34.97%
3 Yr 12.6%* 3.8% 59.5% 79.02%
5 Yr 6.3%* 1.0% 36.9% 90.71%
10 Yr 17.4%* 9.8% 21.3% 35.77%

* Annualized

Return Ranking - Calendar

Period IBB Return Category Return Low Category Return High Rank in Category (%)
2020 25.7% -13.6% 178.2% 15.53%
2019 25.0% 3.8% 63.8% 23.45%
2018 -9.7% -49.7% 21.5% 67.88%
2017 -59.8% -59.8% 54.4% 100.00%
2016 -21.6% -36.6% 11.6% 81.40%

Total Return Ranking - Trailing

Period IBB Return Category Return Low Category Return High Rank in Category (%)
YTD 6.7% 1.3% 15.8% 13.95%
1 Yr 25.9% -2.3% 180.5% 33.13%
3 Yr 12.6%* 2.4% 59.5% 74.13%
5 Yr 6.3%* 1.0% 36.9% 90.71%
10 Yr 17.4%* 9.8% 21.3% 34.15%

* Annualized

Total Return Ranking - Calendar

Period IBB Return Category Return Low Category Return High Rank in Category (%)
2020 25.7% -13.6% 178.2% 15.53%
2019 25.0% 3.8% 63.8% 23.45%
2018 -9.7% -25.3% 22.2% 70.80%
2017 20.7% -10.8% 54.4% 52.59%
2016 -21.6% -36.6% 11.6% 87.60%

IBB - Holdings

Concentration Analysis

IBB Category Low Category High IBB % Rank
Net Assets 10.4 B 6.3 M 49 B 8.14%
Number of Holdings 289 24 459 3.49%
Net Assets in Top 10 4.35 B 1.2 M 19.6 B 5.81%
Weighting of Top 10 42.52% 8.8% 76.9% 34.88%

Top 10 Holdings

  1. Amgen Inc 8.03%
  2. Regeneron Pharmaceuticals Inc 6.51%
  3. Regeneron Pharmaceuticals Inc 6.51%
  4. Regeneron Pharmaceuticals Inc 6.51%
  5. Regeneron Pharmaceuticals Inc 6.51%
  6. Regeneron Pharmaceuticals Inc 6.51%
  7. Regeneron Pharmaceuticals Inc 6.51%
  8. Regeneron Pharmaceuticals Inc 6.51%
  9. Regeneron Pharmaceuticals Inc 6.51%
  10. Regeneron Pharmaceuticals Inc 6.51%

Asset Allocation

Weighting Return Low Return High IBB % Rank
Stocks 		99.83% 77.04% 104.32% 25.00%
Cash 		0.17% -0.10% 12.53% 77.33%
Preferred Stocks 		0.00% 0.00% 5.23% 27.91%
Other 		0.00% -27.80% 10.43% 42.44%
Convertible Bonds 		0.00% 0.00% 0.06% 18.02%
Bonds 		0.00% 0.00% 19.34% 23.26%

Stock Sector Breakdown

Weighting Return Low Return High IBB % Rank
Healthcare 		100.00% 61.64% 100.00% 7.56%
Utilities 		0.00% 0.00% 0.00% 17.44%
Technology 		0.00% 0.00% 15.86% 29.65%
Real Estate 		0.00% 0.00% 5.95% 23.26%
Industrials 		0.00% 0.00% 5.94% 25.00%
Financial Services 		0.00% 0.00% 4.10% 47.67%
Energy 		0.00% 0.00% 0.03% 18.02%
Communication Services 		0.00% 0.00% 4.69% 20.93%
Consumer Defense 		0.00% 0.00% 33.59% 23.84%
Consumer Cyclical 		0.00% 0.00% 1.19% 25.58%
Basic Materials 		0.00% 0.00% 3.30% 38.95%

Stock Geographic Breakdown

Weighting Return Low Return High IBB % Rank
US 		90.10% 56.44% 100.00% 23.84%
Non US 		9.73% 0.00% 41.69% 73.26%

IBB - Expenses

Operational Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.46% 0.08% 25.14% 86.23%
Management Fee 0.46% 0.00% 1.25% 15.70%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IBB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 29.00% 0.70% 252.00% 32.32%

IBB - Distributions

Dividend Yield Analysis

IBB Category Low Category High IBB % Rank
Dividend Yield 0.15% 0.00% 1.05% 11.05%

Dividend Distribution Analysis

IBB Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annually Monthly Quarterly

Net Income Ratio Analysis

IBB Category Low Category High IBB % Rank
Net Income Ratio 0.24% -2.53% 1.74% 35.12%

Capital Gain Distribution Analysis

IBB Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

IBB - Fund Manager Analysis

Managers

Greg Savage

Start Date

Tenure

Tenure Rank

Jan 01, 2008

13.01

13.0%

Greg Savage, Managing Director; has been associated with BlackRock Fund Advisors since 2009. Mr. Savage has been a senior portfolio manager for BFA and BTC since 2009. Prior to his employment with BFA and BTC, Mr. Savage was a senior portfolio manager from 2006 to 2009 for BGFA and BGI and a portfolio manager from 2001 to 2006 for BGFA and BGI.

Jennifer Hsui

Start Date

Tenure

Tenure Rank

Aug 01, 2012

8.42

8.4%

Jennifer Hsui has been employed by BlackRock Fund Advisors as a senior portfolio manager since 2007. Prior to that, Ms. Hsui was a portfolio manager from 2006 to 2007 for BGFA. She was a research analyst for RBC Capital Markets from 2003 to 2006.

Alan Mason

Start Date

Tenure

Tenure Rank

Apr 15, 2016

4.72

4.7%

Alan Mason is a Managing Director of BlackRock Advisors, LLC since 2009. Previously, Mr. Mason was a Managing Director of Barclays Global Investors from 2008 to 2009 and a Principal from 1996 to 2008.

Amy Whitelaw

Start Date

Tenure

Tenure Rank

Aug 01, 2018

2.42

2.4%

Amy Whitelaw is Managing Director of BlackRock, Inc. since 2013 and was Director of the firm from 2009 to 2012. Ms. Whitelaw's service with the firm dates back to 1998, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Ms. Whitelaw served as Principal of BGI from 2000 to 2009. Previously Ms. Whitelaw worked in the Transition Services group as a transition manager and strategist, and was also an international equity trader on BGI’s trading desk.

Rachel Aguirre

Start Date

Tenure

Tenure Rank

Aug 01, 2018

2.42

2.4%

Rachel Aguirre is a Managing Director of BlackRock, Inc. since 2018. Rachel Aguirre has been with BlackRock since 2006, including her years with Barclays Global Investors (“BGI”), which merged with BlackRock in 2009.Ms. Aguirre was previously a Director of BlackRock, Inc. from 2012 to 2017, Vice President of BlackRock, Inc. from 2009 to 2011 and Principal and Portfolio Manager of Barclays Global Investors from 2005 to 2009.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 23.31 7.3 20.68

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.